Lung cancer's quiet revolution: new drugs nearly double survival — and brain radiation is on the way out

At this year's World Conference on Lung Cancer in 2026, one number kept surfacing: 14.3 months. That's how long patients with a rare, aggressive form of lung cancer stayed progression-free on a new first-line treatment called trastuzumab deruxtecan — a full six months longer than the old standard of care.

The phase 3 DESTINY-Lung04 trial was the first global study to prove a single-agent drug could beat pembrolizumab plus chemotherapy for HER2-mutant non-small cell lung cancer (HR 0.63; P<0.0001). For a disease long considered stubbornly difficult to treat, the numbers are striking. But they're just one thread in a much larger story unfolding across oncology — a story where treatments are becoming smarter, kinder, and more personal.

The lung cancer revolution

Across the IASLC 2026 WCLC stage, researchers unveiled a wave of advances for lung cancer, the world's deadliest cancer. The REZILIENT 3 trial showed that adding zipalertinib to chemotherapy cut the risk of progression or death by half in patients with EGFR exon 20 insertion mutations — nearly 50% risk reduction (HR 0.50; P=0.00015), with a benefit even among those with brain metastases (HR 0.38).

Meanwhile, the HARMONi-2 trial delivered a surprise: ivonescimab, a first-in-class bispecific antibody, improved both progression-free survival (11.1 vs. 5.8 months) and — in a prespecified interim analysis — overall survival compared with pembrolizumab, the longtime checkpoint inhibitor king, in PD-L1-positive advanced NSCLC.

Then came the most counterintuitive finding of all. Years of dogma held that small-cell lung cancer patients should receive preventive brain radiation (PCI) after treatment. But the SWOG S1827 MAVERICK trial flipped that logic: 304 patients who got MRI surveillance alone actually had better cognitive failure-free survival than those who received PCI on top of MRI. In an era of routine MRI, the toxic radiation may simply no longer be worth its cost to the brain.

Beyond the lung

The momentum extends far beyond thoracic oncology. At Weill Cornell Medicine, researchers published in Nature Genetics how interferon-alpha forces mutant blood stem cells to mature into short-lived white blood cells, depleting the pool of cancerous cells in myeloproliferative neoplasms — and pointing toward more targeted therapies with fewer side effects.

At MD Anderson, a phase I/II trial showed that fecal microbiota transplantation helped nearly 77% of the first 13 patients with immunotherapy-related colitis see symptoms subside in a median of just 1.5 days. Eight of 10 responders stayed in remission, and many resumed their cancer treatment — all without the steroids that can wreak havoc on patients' health.

And at the University of Virginia, psychiatrist Anita H. Clayton led a study of 480 patients finding that the add-on drug lumateperone significantly improved sexual function across desire, arousal, orgasm and pleasure. With roughly 68% of people with major depressive disorder experiencing sexual dysfunction — a leading reason patients abandon antidepressants — this one is quietly life-changing for millions.

The connective tissue

Strip away the disease names and these breakthroughs share a common DNA. Each one is about doing less harm: fewer chemo doses, no skull radiation, fewer steroids, gentler antidepressants. Each one leans on precision — reading a tumor's genetic signature, profiling stem cells at single-cell resolution, or rebalancing the microbiome.

As Adam Schoenfeld, the MSK researcher presenting early data on a novel SCLC combination, put it: the manageable safety profile and encouraging responses "support further clinical development."

What's hopeful here isn't just the new medicines. It's the direction of the field itself — toward treatments tailored to the individual, calibrated to spare the brain and the body, and measured not just in months lived but in quality of the living.

For the patient asking their oncologist what's next, the answer is more specific than ever before.